



ΣΤΑΥΡΟΥΛΑ ΜΠΑΡΙΤΑΚΗ
Επικ. Καθηγήτρια Πειραματικής Ογκολογίας
Ιατρική Σχολή Πανεπιστημίου Κρήτης

Στοιχεία επικοινωνίας: Ωρίωνος 83, Πρασσάς, Ηράκλειο Κρήτης, 71500
Τηλ: 2810 394727 (γραφείο), 6974101609
e-mail: baritaks@uoc.gr

ΤΙΤΛΟΙ ΣΠΟΥΔΩΝ

- 1998 – 2003** Διδακτορικό δίπλωμα (Ph.D) στη ‘Μοριακή Βιολογία-Βιοιατρική’ (Β.Ε. “Άριστα”) Διατμηματικό πρόγραμμα Βιολογίας-Ιατρικής Πανεπιστημίου Κρήτης
- 1996 – 1998** Μεταπτυχιακός Τίτλος Ειδίκευσης (M.Sc.) στη Μοριακή Βιολογία. (Β.Ε. 9.06, “Άριστα”) Διατμηματικό πρόγραμμα Βιολογίας-Ιατρικής Πανεπιστημίου Κρήτης
- 1992 – 1996** Πτυχίο Βιολογίας (Β.Ε. 7.80, ‘Λίαν Καλώς’) Τμήμα Βιολογίας Παν/μίου Κρήτης, Σχολή Θετικών Επιστημών.

ΑΚΑΔΗΜΑΙΚΕΣ ΘΕΣΕΙΣ

- 9/2014 - Επίκουρη Καθηγήτρια Πειραματικής Ογκολογίας**
Τομέας Χειρουργικής, Ιατρική Σχολή Πανεπιστημίου Κρήτης
- 2014-2015: Σε άδεια παράλληλης απασχόλησης στις ΗΠΑ
 - Μονιμοποίηση: ΦΕΚ 1522/Γ/29-9-2020
- 2013 – 2015 Συνεργαζόμενη ερευνήτρια - Program Leader**
Center for Systems Biomedicine (CSBM)
David Geffen School of Medicine
University of California, Los Angeles (UCLA), USA
- 2012 – 2015 Research Assistant Professor**
Division of Digestive Diseases
UCLA School of Medicine, USA
- 2011 – 2012 Visiting Assistant Researcher**
Cancer Immunotherapy Group, Division of Surgical Oncology
UCLA School of Medicine, USA

2006 – 2011 Postdoctoral Fellow

Department of Microbiology, Immunology and Molecular Genetics
UCLA School of Medicine, USA

2003 – 2006 Συμβασιούχος ΠΔ 407/80

Εργαστήριο Ιολογίας, Κλινικοεργαστηριακός Τομέας
Ιατρική Σχολή Πανεπιστημίου Κρήτης

ΜΕΤΑΔΙΔΑΚΤΟΡΙΚΗ ΕΡΕΥΝΗΤΙΚΗ ΕΜΠΕΙΡΙΑ

9/2016 - Head of Experimental Oncology Laboratory

Τομέας Χειρουργικής, Ιατρική Σχολή Πανεπιστημίου Κρήτης

- Διερεύνηση του ρόλου των νευροπεπτιδίων της οικογένειας CRF στους μηχανισμούς ανοσοδιαφυγής και χαμηλής χημειο-απόκρισης κακοηθειών του γαστρεντερικού συστήματος
- Μελέτη του ρυθμιστικού ρόλου νευροπεπτιδίων που ελέγχουν το stress στη σηματοδότηση φλεγμονής και ογκογένεσης στο έντερο.
- Εντοπισμός μακρών μη κωδικοποιητικών RNAs (lncRNAs) ως βιομάρτυρες (biomarkers) καρκινικών βλαστικών κυττάρων (ΚΒΚ); Ανάλυση του λειτουργικού τους ρόλου στα ΚΒΚ; Θεραπευτική στόχευση
- Μεταγραφική ρύθμιση του γονιδίου BCMA σε αιματολογικές κακοήθειες
- Χρήση τεχνολογικών πλατφόρμων υψηλής απόδοσης (high throughput technology platforms) για μελέτες ανάλυσης του συνολικού γονιδιακού και πρωτεϊνικού δυναμικού διαφορετικών κακοηθειών ('omics' profiling), εντοπισμό βιοδεικτών και ανάπτυξη νέων αντι-νεοπλαστικών θεραπειών

2013 – 2015 Program Leader

Center for Systems Biomedicine (CSBM), UCLA School of Medicine, USA

- Μελέτη του ρόλου των μακρών μη κωδικοποιητικών RNAs (lnc-RNAs) στις ιδιότητες των καρκινικών βλαστικών κυττάρων με προσεγγίσεις συστημικής βιο-ιατρικής (System Biomedicine)

2012 – 2015 Research Faculty

Division of Digestive Diseases David Geffen School of Medicine, University of California, UCLA School of Medicine, USA

- Διερεύνηση του ρόλου των νευροπεπτιδίων της οικογένειας CRF και των υποδοχέων τους στην ανάπτυξη κακοήθειας στο παχύ έντερο

2011 – 2012 Visiting Assistant Researcher

Cancer Immunotherapy/Signal Transduction Group, Division of Surgical Oncology,
UCLA School of Medicine, USA

- Μελέτη των μοριακών μηχανισμών αντοχής κυττάρων μελανώματος σε θεραπεία με χρήση γενετικά τροποποιημένων κυτταροτοξικών CD8+ T λεμφοκυττάρων κατ' αποδοχή [adoptive cell therapy (ACT)], ικανά να αναγνωρίζουν τους επιτόπους MART-1+/HLA-A*0201+ στην επιφάνεια των κυττάρων του μελανώματος.

2006 – 2011 Postdoctoral Fellow

Department of Microbiology, Immunology and Molecular Genetics
UCLA School of Medicine, USA

- Μελέτη των μοριακών μηχανισμών αντοχής καρκινικών κυττάρων σε συμβατική χημειοθεραπεία και ανοσομεσολαβούμενη κυτταροτοξικότητα.
- Μοριακή βάση των πρώιμων σταδίων της μεταστατικής διαδικασίας στον καρκίνο (oncogenic Epithelial to Mesenchymal Transition, EMT)
- Μελέτη της προ-αποπτωτικής και αντι-μεταστατικής βιολογικής δράσης νέων αναστολέων προτεοσώματος (proteasome inhibitors) και μονοκλωνικών αντισωμάτων σε συμπαγείς και αιματολογικές κακοήθειες.

2003 – 2006 Συμβασιούχος ΠΔ407/80

Εργαστήριο Ιολογίας, Κλινικοεργαστηριακός Τομέας
Ιατρική Σχολή Πανεπιστημίου Κρήτης

- Μελέτη γενετικών αλλοιώσεων σε πρωτο-ογκογονίδια, ογκοκατασταλτικά γονίδια και ιικά ογκογονίδια με εμπλοκή σε διάφορους τύπους καρκίνου.
- Ανάπτυξη και εφαρμογή του πρώτου ανοιχτού διαγνωστικού προγράμματος ανίχνευσης και τυποποίησης ιικών στελεχών σε βιολογικά υγρά σώματος με τεχνικές μοριακής βιολογίας, σε συνεργασία με το ΠΑΓΝΗ

2004/2005 Visiting UICC and EARC Research Scholar

Department of Microbiology, Immunology and Molecular Genetics, UCLA, USA.

- Έκφραση και κλινική σημασία του μεταγραφικού παράγοντα YY1 στην κακοήθεια του προστάτη

2003 EMBO Research Scholar

Department of Virology, Institute of Hygiene, University of Heidelberg, GERMANY.

- Μελέτη της επίδρασης συνθετικών V3 πεπτιδίων στη μόλυνση πρωτογενών μακροφάγων και CD4+ T κυτταρικών σειρών από στελέχη του ιού HIV-1.

ΔΙΔΑΚΤΙΚΗ ΕΜΠΕΙΡΙΑ

2020 **Εκπαιδευτρια** στον 7ο κύκλο σπουδών (2020-2021) της Ελληνικής Ακαδημίας Ογκολογίας (Ε.ΑΚ.Ο) υπό την αιγίδα της Ένωσης Ογκολόγων-Παθολόγων Ελλάδας (Ε.Ο.Π.Ε).

2017 – **Μέλος ΔΕΠ - Ιατρική Σχολή Πανεπιστημίου Κρήτης**

Ανάθεση

Υπεύθυνη για τη διδασκαλία του παρακάτω προπτυχιακού μαθήματος

- ‘Ανοσολογία του καρκίνου’ (4ο εξάμηνο, κατ’ επιλογήν, Τομέας Χειρουργικής)

Συμμετοχή

Συμμετοχήστη διδασκαλία των παρακάτω προπτυχιακών μαθημάτων:

- ‘Βιολογία Α’ (1^ο εξάμηνο, Τομέας Βασικών Επιστημών)
- ‘Βιολογία Β’ (2ο εξάμηνο, Τομέας Βασικών Επιστημών)
- ‘Βασική Ανοσολογία’ (3ο εξάμηνο, Τομέας Παθολογίας)
- ‘Βασικές αρχές ογκογένεσης’ (3^ο εξάμηνο, κατ’ επιλογήν, Τομέας Παθολογίας)

2010 – 2015 **Research Faculty - UCLA School of Medicine, USA**

Department of Microbiology, Immunology and Molecular Genetics.

Υπεύθυνη διδασκαλίας πολλαπλών εξαμηνιαίων θεματικών ενοτήτων στα πλαίσια του **μεταπτυχιακού μαθήματος “Ανοσολογία του καρκίνου”** (Immunobiology of cancer, Seminar 262C). Θεματολογία:

- Targeted pharmacologic inhibitors to reverse resistance to immunotherapy
- Cross-talk between epithelial to mesenchymal transition (EMT) and immunoresistance
- Foxp3 Tregs as targets for tumor immunity: failures and successes
- Emerging axis of cancer stem cells, EMT and immune-resistance
- Antibody–drug conjugates (ADCs) in cancer therapy

2003 - 2006 **Συμβασιούχος ΠΔ 407/80 - Ιατρική Σχολή Πανεπιστημίου Κρήτης**

Υπεύθυνη διδασκαλίας των παρακάτω προπτυχιακών μαθημάτων:

- Κλινική Ιολογία (5ο εξάμηνο, Κλινικοεργαστηριακός Τομέας)
- Μοριακή Ογκολογία’ (5ο εξάμηνο, Κλινικοεργαστηριακός Τομέας)

1997 - 1999 **Graduate Student - Τμήμα Βιολογίας, Πανεπιστημίου Κρήτης.**

Συμμετοχή στη διεξαγωγή των παρακάτω προπτυχιακών εργαστηρίων:

- Βιοχημεία I, II (4ο και 5ο εξάμηνο)
- Ανοσολογία (5^ο εξάμηνο)

1998 – 2000 Συμβασιούχος Εκπαιδευτρια - Δημόσια Ινστιτούτα Επαγγελματικής Κατάρτισης (ΙΕΚ), Ηράκλειο Κρήτης

Υπεύθυνη διδασκαλίας των παρακάτω θεωρητικών και εργαστηριακών μαθημάτων:

- Ανοσολογία (θεωρία και εργαστήριο), (85 ώρες)
- Βιοχημεία (θεωρία και εργαστήριο), (90 ώρες)
- Παχυσαρκία και μεταβολισμός (40 ώρες, θεωρία)

ΕΚΠΑΙΔΕΥΣΗ ΦΟΙΤΗΤΩΝ - ΕΠΙΒΛΕΨΗ ΔΙΑΤΡΙΒΩΝ – ΜΕΛΟΣ ΕΠΙΤΡΟΠΩΝ

- Μέλος τριμελών επιτροπών για εκπόνηση Μεταπτυχιακού Τίτλου Ειδίκευσης ή/και Διδακτορικής Διατριβής.

Τμήμα Ιατρικής Πανεπιστημίου Κρήτης

- Γιασεμή Επταμηνιτάκη [Υποψ. Διδάκτορας (Έναρξη 2020) – Ρόλος: **Επιβλέπουσα**]

Τμήμα Επιστήμης και Τεχνολογίας Υλικών (ΤΕΤΥ) Πανεπιστημίου Κρήτης

- Μαρία Ψαρού [M.sc: (2017-2019) – Ρόλος: **Μέλος**]
- Μαρία Ψαρού [Υποψ. Διδάκτορας (Έναρξη 2019) – Ρόλος: **Μέλος**]

David Geffen School of Medicine, University of California, Los Angeles (UCLA), USA

- Jonathan Gevrokian [Msc (2014-2015) – Ρόλος: **Επιβλέπουσα**]
- Jorge Rodriguez [Msc (2012-2014) – Ρόλος: **Επιβλέπουσα**]

- Συμμετοχή στην **ανάπτυξη, καθοδήγηση και επίβλεψη** ερευνητικών πρωτοκόλλων και επιστημονικών εργασιών με εξειδικευμένη εκπαίδευση υποψηφίων σε εργαστηριακές τεχνικές Βιοχημείας, Κυτταρικής και Μοριακής Βιολογίας, στα πλαίσια εκπόνησης διπλωματικών, μεταπτυχιακών και διδακτορικών διατριβών.

Ιατρική Σχολή Πανεπιστημίου Κρήτης

- Βενιανάκη Μαρία (Υποψ. Διδάκτορας, 2017-)
- Ιωάννης Λυρώνης (P.hD: 2006)
- Σταύρος Αποστολάκης (P.hD: 2006)
- Παναγιώτα Κανέλλου (P.hD: 2006)
- Ανθούλα Βάκη (Υποψ. Διδάκτορας, 2004-)
- Συμεών Παναγιωτάκης (Ph.D: 2006)
- Βίκτωρας Γκούρβας (Ph.D: 2006)
- Πέπη Δάλπα (Ph.D: 2007)
- Διομήδης Κοζυράκης (Ph.D: 2007)

David Geffen School of Medicine, University of California, Los Angeles (UCLA), USA

- Anna Sahakyan (Ph.D: 2011)

- Aaron Chapman (Ph.D: 2010)
- Alina Katsman (Pre-med fellow, 2006-2008)
- Katherin Wu (Pre-med fellow, 2006-2009)
- Kiberly Lin (M.sc: 2008)

Ινστιτούτο Μοριακής Βιολογίας και Βιοτεχνολογίας, ΙΤΕ

- Γιώργος Κουτσουδάκης (Msc: 2002)
- Φίλιππος Πορίχης (PhD: 2003)

ΥΠΟΤΡΟΦΙΕΣ / ΒΡΑΒΕΙΑ / ΔΙΑΚΡΙΣΕΙΣ

- Invited Author and Editor of the book: 'Prognostic and Therapeutic Applications of RKIP in Cancer, Elsevier, 1st Edition, ISBN: 978-0-12-81 9612-0, 3/2/2020
- Talk of Distinction, Digestive Disease Week (DDW), Washington DC, USA, 2015
- Young Investigator Career Development Award by the University of California, Los Angeles (UCLA) CURE: Digestive Diseases Research Center (CURE:DDRC) and the UCLA Clinical and Translational Science Institute (CTSI) for exceptional research proposal quality and innovation in gastrointestinal malignancies, (2014-2015), 2014
- Poster of Distinction, CURE:DDRC annual meeting, University of California, Los Angeles (UCLA) Medical School, 2014
- Nominated by the Department of Microbiology and Immunology, University of California, Los Angeles (UCLA) for the Chancellor's Postdoctoral Award for Outstanding Accomplishments in Research, 2009
- American Society of Hematology (ASH) Travel Award, 2009
- American Association of Cancer Research (AACR) Award for best oral research presentation at AACR annual meeting, San Diego, CA, 2008
- The Bodosaki Foundation Career Development Award for postdoctoral research in USA, (2008-2011)
- American Society of Hematology (ASH) Travel Award, 2007
- UICC International Cancer Technology Transfer Fellowship Award for postdoctoral training at University of California, Los Angeles (UCLA), 2005
- European Association for Cancer (EACR) short term fellowship Award for postdoctoral training at University of California, Los Angeles (UCLA), 2004
- Elected life member of the Union of International Cancer Control (UICC) fellows, 2004
- EMBO short term fellowship Award for graduate training at the University of Heidelberg, Germany, 2002
- Best oral presentation Award by the Greek Society of Medicine, Annual Meeting 2000
- Fellowship by the 3rd Community Support framework of the European Commission for graduate studies (PhD) at the Institute of Molecular Biology and Biotechnology (IMBB), FORTH (1998-2002)
- Best oral presentation Award by the Greek Society in Hematology, Annual Meeting 1998
- Fellowship by the 2nd Community Support framework of the European Commission for graduate studies (Msc) at the Institute of Molecular Biology and Biotechnology (IMBB), FORTH (1997-1998)
- National Foundation Scholarship Awards for academic excellence in the Department of Biology, University of Crete during the academic years 1992-1993, 1993-1994 and 1994-1995

- National Foundation Scholarship Award for ranking 2nd in the National written exams for entry in the Department of Biology, University of Crete during the academic year 1992-1993

ΕΥΡΕΣΙΤΕΧΝΙΕΣ

- “Χρήση του νέου αναστολέα πρωτεοσώματος Salinosporamide A (NPI-0052) για αναστολή της μετάστασης καρκινικών κυττάρων από κακοήθειες του προστάτη”

U.S. Patent Application Serial No. 12/423,713, filed 4/14/2009

‘USE OF SALINOSPORAMIDE A TO INHIBIT METASTASIS’

Inventors: Stavroula Baritaki, Benjamin Bonavida, Emmanuel Palladino

ΣΥΝΕΡΓΑΣΙΕΣ ΜΕ ΑΛΛΑ ΠΑΝΕΠΙΣΤΗΜΙΑ – ΕΡΕΥΝΗΤΙΚΑ ΚΕΝΤΡΑ / ΕΡΓΑΣΤΗΡΙΑ

- UCLA David Geffen Medical School, Division of Digestive Diseases, USA (Prof. C. Pothoulakis)
- UCLA David Geffen Medical School, Center for Systems Biomedicine, USA (Dr. E. Faure)
- UCLA Department of Microbiology, Immunology and Molecular Genetics, USA (Profs. B. Bonavida, E. Penichet)
- Johannes Gutenberg University, Institute of Pharmacy and Biochemistry, Department of Pharmaceutical Biology, Mainz, Germany (Prof. T. Efferth)
- University of Udine, Department of Medical Sciences, Italy (Prof. Valentina Rapozzi)
- University of Catania, School of Medicine, Department of Biomedical and Biotechnological Sciences, Center of Prevention, Diagnosis and Treatment of Cancer, Italy (Prof. Massimo Libra)
- European University Cyprus, Department of Life Sciences, Cancer Genetics Laboratory, Cyprus (Prof. A. Zaravinos)
- University of Chicago, Ben May Department for Cancer Research, USA (Prof. M. Rosner)
- University of Toledo, Department of Biochemistry and Cancer Biology, USA (Prof. K. Yeung)
- Ιατρική Σχολή Πανεπιστημίου Αλεξανδρούπολης, Εργ. Φαρμακολογίας (Καθ. Κ. Χατζάκη)
- Ιδρυμα Ιατροβιολογικών Ερευνών, Αθήνα (Ερευνητής. Δ. Στέλλας)
- Unidad de Investigacion en Enfermedades Oncologicas, Hospital Infantil de México Federico Gomez, Mexico City, Mexico (Prof. S. Huerta-Yepez)

ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΙΩΝ

- Ελληνική Ακαδημία Ογκολογίας (Ε.ΑΚ.Ο) (2019-σήμερα)
- World Hellenic Biomedical Association (WHBA) (2012-σήμερα)
- American Gastroenterology Association (AGA) (2012- σήμερα)
- American Association for Cancer Research (AACR) (2006-σήμερα)
- American Society of Hematology (ASH) (2006- σήμερα)
- Life member of the Union for International Cancer Control (UICC) Fellows (2004-σήμερα)

- European Association for Cancer Research (EACR) (2003-σήμερα)

ΑΛΛΕΣ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ

- **2009-σήμερα** Κριτής σε 24 SCI-indexed βιοιατρικά επιστημονικά περιοδικά συμπεριλαμβανομένων μεταξύ άλλων των:
 - Cancer Research (IF: 9,727)
 - Gastroenterology (IF:20,877)
 - Cell Death and Disease (IF: 10.717)
 - Cellular and Molecular Gastroenterology & Hepatology (IF: 7,076)
 - International Journal of Cancer (IF: 7,36)
 - European Journal of Cancer (IF: 7,275)
 - Cancer Letters (IF: 7,36)
 - Cancers (IF: 6,162)
 - International Journal of Molecular Sciences (IJMS) (IF: 4.556)
- **2020 – σήμερα** Μέλος του Μητρώου Πιστοποιημένων Αξιολογητών - Εμπειρογνομόνων του Ελληνικού Ιδρύματος Έρευνας και Καινοτομίας (ΕΛΙΔΕΚ) για την κρίση ερευνητικών προτάσεων
- **2013-2017** Κριτής σε ερευνητικά προγράμματα του Εθνικού Ινστιτούτου Υγείας των ΗΠΑ.
- Διοργάνωση των κάτωθι Διεθνών Συνεδρίων
 - **2nd International workshop on prognostic and therapeutic implication of RKIP in cancer.** Μάιος 2019, Ηράκλειο Κρήτης
 - **1st International workshop on prognostic and therapeutic implication of RKIP in cancer.** Μάρτιος 2010, Los Angeles, CA, USA.
- Μέλος της Οργανωτικής Επιτροπής των κάτωθι Διεθνών Συνεδρίων:
 - **11th World Congress on Advances in Oncology & 9th International Symposium on Molecular Medicine,** Οκτ. 2006, Χερσόνησος Κρήτης.
 - **10th World Congress on Advances in Oncology & 8th International Symposium on Molecular Medicine,** Οκτ. 2005, Χερσόνησος Κρήτης.
 - **9th World Congress on Advances in Oncology & 7th International Symposium on Molecular Medicine,** Οκτ. 2004, Χερσόνησος Κρήτης.
 - **8th World Congress on Advances in Oncology & 6th International Symposium on Molecular Medicine,** Οκτ. 2003, Χερσόνησος Κρήτης.

ΔΙΟΙΚΗΤΙΚΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ

- Μέλος της «Γενικής Συνέλευσης» της Ιατρικής Σχολής του Πανεπιστημίου Κρήτης (**2020-σήμερα**)
- Μέλος της «Επιτροπής Έρευνας και Ερευνητικών Υποδομών» της Ιατρικής Σχολής Πανεπιστημίου Κρήτης (**2020-σήμερα**)
- Μέλος της «Επιτροπής Χωροταξίας» της Ιατρικής Σχολής Πανεπιστημίου Κρήτης (**2020-σήμερα**)
- Μέλος της «Επιτροπής Διασύνδεσης με την Κοινωνία – Εθελοντισμός» της Ιατρικής Σχολής Πανεπιστημίου Κρήτης (**2019-σήμερα**)

ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ ΑΠΟ ΑΝΤΑΓΩΝΙΣΤΙΚΑ ΕΡΕΥΝΗΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ

➤ Τρέχοντα ερευνητικά προγράμματα

1. ΕΛΛΗΝΙΚΟ ΙΔΡΥΜΑ ΕΡΕΥΝΑΣ & ΚΑΙΝΟΤΟΜΙΑΣ (ΕΛΙΔΕΚ).

1η Προκήρυξη ερευνητικών έργων ΕΛΙΔΕΚ για την ενίσχυση των μελών ΔΕΠ και Ερευνητών/τριών και την προμήθεια ερευνητικού εξοπλισμού μεγάλης αξίας ,

‘LncRNAs: A new class of biomarkers for therapeutic targeting of cancer stem cells’, 2020-2023, €200.000
(Επιστημονικά Υπεύθυνη)

2. ΕΙΔΙΚΟΣ ΛΟΓΑΡΙΑΣΜΟΣ ΚΟΝΔΥΛΙΩΝ ΕΡΕΥΝΑΣ (ΕΛΚΕ) ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΚΡΗΤΗΣ

Ερευνητικές προτάσεις Μεγάλου μεγέθους τύπου Β

(ΕΛΚΕ: ΚΑ: 10419) ‘Impact of stress regulators on colon cancer immunoescape’, 2019-2021, €10.000
(Επιστημονικά Υπεύθυνη)

3. ΕΞΩΤΕΡΙΚΟΙ ΧΡΗΜΑΤΟΔΟΤΕΣ (Elsevier, Coming Century Co, International Assosiation on the Immunobiology of Proteins and Peptides)

(ΕΛΚΕ: ΚΑ: 10183) ‘Prognostic and Therapeutic Implications of RKIP in Cancer’, 2019-2022, €35.000
(Επιστημονικά Υπεύθυνη)

➤ Ολοκληρωμένα ερευνητικά προγράμματα

1. 5R01DK101671-03 NIH Grant: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

‘Role of Corticotropin Releasing Hormone in Intestinal Inflammation’,
1/2/2015-31/7/2018, \$346,500.

2. UCLA CURE: DDRC Career Development Grant (PFS DK#41301), USA

‘Role of corticotropin releasing hormone receptor 2 (CRHR2) in colon cancer immunoescape’, 5/2014-7/2015, \$30,000. (Επιστημονικά Υπεύθυνη)

3. Biomedics and Biosearch, Inc., Japan, Sponsored Research Agreement (SRA), USA

‘Novel anti-CD20 antibodies against Non-Hodgkin’s Lymphomas (NHL)’,
1/2011-5/2011, \$30,000 (Επιστημονικά Υπεύθυνη)

3. Bodosaki Foundation career development award

‘The role of YY1 in prostate cancer resistance to chemotherapy and immune-mediated apoptosis’
9/2008-9/2011, €100,000 (Επιστημονικά Υπεύθυνη)

4. Nereus Pharmaceutical, USA, Sponsored Research Agreement (SRA), USA, USA ‘Investigation of the role of the natural proteasome inhibitor NPI-0052 in tumor cell resistance and EMT in human cancers’, 1/2008-1/2010, Total Budget: \$200,000. (Συνεργαζόμενη ερευνήτρια)

5. RO1 HL28543-01 A2 NIH Grant: National Heart, Lung and Blood Institute, USA, ‘Involvement of Yin Yang 1 (YY1) and Raf-1 kinase inhibitor protein (RKIP) in the pathogenesis of Burkitt’s and DLBCL and prognostic significance’, 5/ 2008-4/2010, \$350.000. (Συνεργαζόμενη ερευνήτρια)

6. Multiple myeloma Research Foundation (MMRF-USA) Research Grant, USA (Validation of Novel Combinations and Compounds), ‘Regulation of RKIP expression in multiple myeloma’, 2/2008-1/2010, \$200,000 (Συνεργαζόμενη ερευνήτρια)

7. **UCLA Human Gene Medicine Program, Research Seed Grant, USA** ‘Reversal of TRAIL resistance in tumor cells by over-expression of the metastasis repressor gene, RKIP’, 6/2007-6/2008, Total Budget: \$ 30,000 (Επιστημονικά Υπεύθυνη)
8. **1 RO1 CA12921-02 S1A1 NIH Grant, USA** ‘Novel proteasome inhibitors in chemo/immuno-therapy and treatment of metastasis’ 3/2007-5/2009, \$512,344 (Συνεργαζόμενη ερευνήτρια)
9. **EACR Short Term Fellowship** for research training at UCLA, USA, 3/2004-8/2004, 2,000 euro.
10. **UICC International Cancer Technology Transfer Fellowship** for research training at UCLA, USA, 4/2005-8/2005, 10,000 euros (Επιστημονικά Υπεύθυνη)
11. **EMBO Short Term Fellowship** for research training at the University of Heidelberg, Germany, 10/2001-3/2002, 7,316 euros (Επιστημονικά Υπεύθυνη)
12. **ΕΛΚΕ Πανεπιστημίου Κρήτης (KA847)**, ‘Qualitative and quantitative identification of viral infections in clinical samples using molecular biology approaches’, 9/2003-9/2007 (Συνεργαζόμενη ερευνήτρια)
13. **European Union Grant QLK5-CT1999-51379**, ‘Study of the immunodeficiency syndrome induced by the V3 region of the gp120 HIV-1 glycoprotein’ 2000-2002, 300,000 euro (Συνεργαζόμενη ερευνήτρια)
14. **General Secretariat of Research and Technology-Hellas Grant 99ED339/PENEΔ’99**, ‘Study of the immunoreactivity and scattering of chemical polymers with biological activity’, 2000-2001, 30,000 euro. (Συνεργαζόμενη ερευνήτρια)
15. **Hellenic Center for Infectious Disease Control (HCIDC) Grant 3065/95**, ‘Study of the effect of synthetic HIV-1-derived V3 peptides in the response of CD4+ T lymphocytes’ 200-2001, 50,000 euros (Συνεργαζόμενη ερευνήτρια)
16. **Individual Fellowships by the 2nd and 3rd Community Support framework of the European Commission (ΕΠΕΑΕΚ)** for graduate studies (M.sc and Ph.D) at the Institute of Molecular Biology and Biotechnology (IMBB), FORTH (1996-2002)
17. **European Union Grant BIO4CT-950252**, ‘Immune-engineering for production of humanized therapeutic monoclonal antibodies’, 1996-1998, 150,000 euros. (Συνεργαζόμενη ερευνήτρια)

ΕΠΙΛΕΓΜΕΝΕΣ ΟΜΙΛΙΕΣ ΜΕΤΑ ΑΠΟ ΠΡΟΣΚΛΗΣΗ

1. **1st International Mini Symposium on the Successes and Challenges on NK Immunotherapy**
Μάρτιος 2020, Los Angeles, CA, USA
‘The role of Nitric Oxide (NO) on NK-mediated cytotoxicity in cancer’
2. **Ελληνική Ακαδημία Ογκολογίας (ΕΑΚΟ), 7ος κύκλος Σπουδών**
Φεβρουάριος 2020, Αθήνα
‘Ανοσολογία και Ανοσοθεραπεία του Καρκίνου’
3. **Συνέδριο Κλινικής και Μεταφραστικής Ογκολογίας 2019**
Νοέμβριος 11-13, 2019, Ηράκλειο Κρήτης
‘lncRNAs: Νέοι βιοδείκτες στα καρκινικά βλαστικά κύτταρα’
4. **Συνέδριο Κλινικής και Μεταφραστικής Ογκολογίας 2018**
Νοέμβριος 15-16, 2018, Ηράκλειο Κρήτης
‘Καρκινογένεση και Βιολογία του Καρκίνου
5. **World Cancer Congress, 2018**
August 13-15, 2018, Rome, ITALY

- 'Stress, Inflammation and colon cancer: A neuropeptide-driven crosstalk'
- 6. International Meeting on Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Disorders**
October 4-5, 2018, Siena, ITALY
"Nitric Oxide: A multifaceted target for reversal of cancer cell pleiotropic properties by NO-modulating therapies"
 - 7. Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania. Translational Oncology & Functional Genomics Laboratory**
December 2018, Catania, ITALY
"Neuropeptide signaling in GI malignancies"
 - 8. Digestive Disease Week (DDW)**
May 2015, Washington DC, USA
"Molecular profiling and functional role of non-coding RNAs (Lnc-RNAs) in pancreatic cancer stem cell (PCSC) biology "
 - 9. UCLA Cure:CTSI Program, Division of Digestive Diseases**
January 2013, Los Angeles, CA, USA
"Raf-1 Kinase Inhibitory Protein (RKIP). A key modulator of cancer cell resistance to apoptosis and metastasis"
 - 10. Memorial Sloan-Kettering Cancer Center (MSKCC), Department of Human Oncology and Pathogenesis**
October 2010, New York, NY, USA
"Regulation of RKIP in cancer"
 - 11. Stony Brook University, Department of Medicine, Division of Cancer Prevention.**
September 2010, Stony Brook, NY, USA.
"RKIP as a novel metastasis-suppressing gene"
 - 12. 1st International meeting on prognostic and therapeutic applications of RKIP in cancer management.**
March 2010, Los Angeles, CA, USA
"Dual roles of Raf-1 kinase inhibitor protein (RKIP) in the regulation of both tumor cell resistance to apoptotic stimuli and epithelial to mesenchymal transition (EMT)"
 - 13. 1st International Workshop on Nitric Oxide in Cancer Therapy.**
September 11-12, 2009, Dijon, FRANCE
Nitric oxide-mediated inhibition of EMT in tumor metastatic prostate cells through suppression of Snail and induction of the metastasis suppressor gene product, RKIP'
 - 14. 1st International Workshop on Prognostic and Therapeutic Roles of Yin Yang 1 in Cancer.**
May 24-26, 2009, Catania, ITALY
"Yin-Yang 1 (YY1) as a tumor immune-suppressor gene product"
 - 15. 11th International Symposium on Molecular Medicine and 13th World Congress on Advances in Oncology.**
October, 2008, Xersonissos, Crete, GREECE.
"Regulation of multiple myeloma cell survival and resistance by overexpression of the phosphorylated form of RAF-1 kinase inhibitor protein (RKIP)"
 - 16. 99th American Association for Cancer Research (AACR) Annual Meeting**
April 2008, San Diego, CA, USA.

"Inhibition of Snail-induced EMT and induction of the tumor metastasis suppressor/immune cancer gene RKIP by the proteasome inhibitor NPI-0052:: Role in chemo/immunosensitization and metastasis"

17. 1st International Conference on Nitric Oxide and Cancer

November 26-28, 2007, Paris, FRANCE

"Pivotal role of RKIP induction in Nitric Oxide (NO) – induced tumor cell sensitization to TRAIL-mediated apoptosis via YY1 inhibition and DR5 over-expression"

18. 49th American Society in Hematology (ASH) Annual Meeting.

December 2007, Atlanta, GA, USA.

"Induction of Raf-1 kinase inhibitory protein (RKIP) by the proteasome inhibitor NPI-0052 and reversal of B-NHL resistance to apoptosis" (Awarded presentation)

19. 10th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology.

October 2007, Xersonissos, Crete, GREECE.

"RKIP as a New Immunosurveillance Gene: Pivotal Role in the Regulation of Tumor Cell Response to Cytotoxic Immunotherapy"

20. 4th International conference in cancer prevention

November 2006, St. Gallen, SWITZERLAND

"Evaluation of VEGF and TGFB1 mRNA expression profiles as markers of malignant transformation in cytological cervical specimens"

21. 9th International Symposium on Molecular Medicine and 11th World Congress on Advances in Oncology.

October 2006, Xersonissos, Crete, GREECE

Identification of novel therapeutic targets in the reversal of Rituximab and drug resistant Non-Hodkins lymphoma: chemosensitization by specific pharmacological inhibitors.

22. ECCO 13 – The European Cancer Conference

November 2005, Paris, FRANCE.

"CDDP sensitizes prostate cancer cells to TRAIL-mediated apoptosis via inhibition of NF- κ B/YY1 pathway"

23. 8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology.

October 2005, Xersonissos, Crete, GREECE

"The Yin-Yang 1 (YY1) transcription repressor regulates tumor cell resistance to apoptotic stimuli: New target for prognosis and therapeutic intervention"

24. 8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology,

October 2005, Xersonissos, Crete GREECE

"Reversal of resistance to apoptotic stimuli by alteration of membrane fluidity; therapeutic implications".

25. 6th International Symposium on Molecular Medicine and 8th World Congress on Advances in Oncology.

October 2003, Hersonissos, Crete, GREECE

"The role of V3 domain in the HIV-1-induced pathogenesis"

26. 5th International Symposium on Molecular Medicine and 7th World Congress on Advances in Oncology

October 2002, Hersonissos, Crete, GREECE

"The importance of ionic charges in the interaction of the HIV-1 V3 principal neutralizing domain with the amino-terminal of CCR5: Implications on T cell function"

27. 4th International Discussion Meeting on Relaxations in Complex Systems.

October 2002, Hersonissos, Crete, GREECE

“Light scattering and immunoreactivity studies of PVP derivatives with amino acid-dependent groups’

ΣΥΓΓΡΑΦΙΚΟ ΕΡΓΟ

A. Ξενόγλωσσες Επιστημονικές Δημοσιεύσεις σε Διεθνή Περιοδικά με Κριτές

Συνολικός αριθμός: **77**

Pubmed indexed: **73**

Συνολικός συντελεστής εμβέλειας (Total IF_{2017/2018}): **300.785**

Μέσος συντελεστής εμβέλειας (Average IF_{2017/2018}): **4.43**

Αναφορές (Citations) (based on Google Scholar): **>3700**

H-index: **35**

i10-index: **67**

*Senior/Corresponding author

Equal contribution

1. Dual effects of non coding RNAs in cancer stem cell biology

Kyriazi AA, Papiris E, Kitsos Kalyvianakis K, Baritaki S.*

Int. J Mol. Sci. 2020; 21(18):E6658 (IF_{2017/2018}: **4.183**)

2. Corticotropin Releasing Factor Receptors in breast cancer: expression and activity in hormone-dependent growth in vitro.

Koureta M, Karaglani M, Panagopoulou M, Balgkouranidou I, Papadaki-Anastasopoulou A, Zarouchlioti C, Dekavallas S, Kolios G, Lambropoulou M, Baritaki S, Chatzaki E.

Peptides 2020; 129:170316 (IF_{2017/2018}: **2.851**)

3. Chronic Stress, inflammation and coloncancer. A CRH System -Driven Molecular Crosstalk

Baritaki S.*, De Bre E, Chatzaki E, Pothoulakis C.

J Clin Med. 2019; 8(10):1669 (IF_{2017/2018}: **5.688**)

4. Current Perspectives in Cancer Immunotherapy

Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A

Cancers (Basel). 2019; 11(10):1472 (IF_{2017/2018}: **6.162**)

5. Do Urocortins hold a potential in treating cardiovascular disease? Review of the current biological and clinical data.

Chatzaki E, Kefala N, Drosos I, Lalidou F, Baritaki S.

Drug Discovery Today. 2019; 24(1):279-284 (IF_{2017/2018}: **6.88**)

6. Nitric Oxide: A multifaceted target for reversal of cancer cell pleiotropic properties by NO-modulating therapies

Baritaki S*, Bonavida B.

Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders. 2019; 311-312

DOI: [10.1016/B978-0-12-816545-4.00016-5](https://doi.org/10.1016/B978-0-12-816545-4.00016-5)

- 7. RKIP: A key rheostat in oncogenic EMT and tumor resistance to apoptosis: Therapeutic targeting and impact**
Zaravinos A, Bonavida B, Chatzaki A, Baritaki S.*
Cancers (Basel). 2018; 10(9):287 (IF_{2017/2018}: **6.162**)
- 8. CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.**
Pothoulakis C, Torre-Rojas M, Duran-Padilla MA, Gevorkian J, Zoras O, Chrysos E, Chalkiadakis G, Baritaki S.*
Int J Cancer. 2018; 142(2):334-346 (IF_{2017/2018}: **7.36**)
- 9. Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer.**
Wottrich S, Kaufhold S, Chrysos E, Zoras O, Baritaki S*, Bonavida B*.
Drug Resist Updat. 2017; 30:28-38 (IF_{2017/2018}: **11.708**)
- 10. Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis.**
Hoffman JM, Baritaki S, Ruiz JJ, Sideri A, Pothoulakis C.
Am J Pathol. 2016 ;186(1):134-44 (IF_{2017/2018}: **4.069**)
- 11. Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling.**
Rodriguez JA, Huerta-Yepez S, Law IK, Baay-Guzman GJ, Tirado-Rodriguez B, Hoffman JM, Iliopoulos D, Hommes DW, Verspaget HW, Chang L, Pothoulakis C, Baritaki S.*
Cell Mol Gastroenterol Hepatol. 2015; 1(6):610-630 (IF_{2017/2018}: **6.85**)
- 12. Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.**
Huerta-Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera-Muñoz M, Rivera-Pazos C, Maldonado-Valenzuela A, Valencia-Hipolito A, Vega MI, Chen H, Berenson JR, Bonavida B.
Int J Oncol. 2014; 45(3):1184-92. (IF_{2017/2018}: **3.571**)
- 13. Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.**
Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S*.
For Immunopathol Dis Therap. 2013; 4(1).
- 14. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.**
Huerta-Yepez S, Baritaki S, Baay-Guzman G, Hernandez-Luna MA, Hernandez-Cueto A, Vega MI, Bonavida B.
Nitric Oxide. 2013; 29:17-24. (IF_{2017/2018}: **4.367**)
- 15. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.**

Ren G*, Baritaki S*, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012; 72(12):3091-104. (IF_{2017/2018}: 9.13)

16. TRAF6 activation in multiple myeloma: a potential therapeutic target.

Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B.

Clin Lymphoma Myeloma Leuk. 2012; 12(3):155-63. (IF_{2017/2018}: 2.308)

17. Galiximab signals B-NHL cells and inhibits the activities of NF- κ B-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.

Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Baritaki S, Vega GG, Hariharan K, Bonavida B.

Mol Cancer Ther. 2012; 11(3):572-81. (IF_{2017/2018}: 5.365)

18 Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF- κ B, YY1 and Snail.

Bonavida B, Baritaki S.*

For Immunopathol Dis Therap. 2012; 3(2):125-133.

19. Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies.

Bonavida B, Huerta-Yepez S, Baritaki S, Vega M, Liu H, Chen H, Berenson J.

Crit Rev Oncog. 2011; 16(3-4):261-7. (RG₂₀₁₄: 4.07)

20. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF- κ B/Snail/YY1/RKIP/PTEN Circuitry.

Bonavida B, Baritaki S.*

Crit Rev Oncog. 2011; 16(3-4):211-26. (RG₂₀₁₄: 4.07)

21. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclox (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.

Martínez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, González-Bonilla C, Bonavida B, Vega MI.

Cell Cycle. 2011; 10(16):2792-805. (IF_{2017/2018}: 3.304)

22. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF- κ B/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.

Baritaki S[#], Militello L[#], Malaponte G, Spandidos DA, Salcedo M, Bonavida B.

Int J Oncol. 2011; 38(6):1683-94. (IF_{2017/2018}: 3.571)

23. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B.

For Immunopathol Dis Therap. 2011; 2(2).

24. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

- Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA.
Curr Cancer Drug Targets. 2011; 11(3):254-84. (IF_{2017/2018}: **2.72**)
- 25. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells.**
Vega MI, Baritaki S, Huerta-Yepe S, Martinez-Paniagua MA, Bonavida B.
Leuk Lymphoma. 2011; 52(1):108-21. (IF_{2017/2018}: **2.674**)
- 26. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF- κ B/Snail/YY1/RKIP circuitry.**
Bonavida B, Baritaki S.*
Nitric Oxide. 2011; 24(1):1-7. (IF_{2017/2018}: **4.367**)
- 27. Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition**
Baritaki S*, Yeung K, Bonavida B
Forum on Immunopathological Diseases and Therapeutics, 2011; 2(1): 95-109
- 28. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP.**
Baritaki S, Huerta-Yepe S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B.
Cell Cycle. 2010; 9(24):4931-40. (IF_{2017/2018}: **3.304**)
- 29. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin.**
Neonakis IK, Samonis G, Messaritakis H, Baritaki S, Georgiladakis A, Maraki S, Spandidos DA.
Chemotherapy. 2010; 56(6):448-52. (IF_{2017/2018}: **2**)
- 30. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF- κ B/Snail/RKIP/PTEN Circuit.**
Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B.
Genes Cancer. 2010; 1(5):409-420. (IF_{2017/2018}: **4.041**)
- 31. Mycobacterium arupense pulmonary infection: antibiotic resistance and restriction fragment length polymorphism analysis.**
Neonakis IK, Gitti Z, Kontos F, Baritaki S, Petinaki E, Baritaki M, Liakou V, Zerva L, Spandidos DA.
Indian J Med Microbiol. 2010; 28(2):173-6.
- 32. Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes.**
Baritaki S*, Bonavida B.
Crit Rev Immunol. 2010; 30(1):31-46. (IF_{2017/2018}: **1.352**)

33. Clinical Significance of YY1 Overexpression in Human Hematopoietic Malignancies

Huerta-Yepe S, Militello L, Baritaki S, Rivera Pazos CM, Cabrera-Muñoz MDL, Vega MI, Libra M, Malaponte G, Canevari S, Castellano G, Chen H, Berenson J.

Forum on Immunopathological Diseases and Therapeutics, 2010; 1(1): 127–139

34. Yin Yang 1 Is a Tumor Immune-Suppressor Gene Product

Baritaki S*

Forum on Immunopathological Diseases and Therapeutics, 2010; 1(1):17-30

35. Clinical Significance of the Inhibition of YY1 Activity and Expression by Therapeutic Anti-Cancer Antibodies

Bonavida B, Huerta-Yepe S, Jazirehi AR, Militello L, Uematsu N, Spandidos D, Baritaki S, Vega M.

Forum on Immunopathological Diseases and Therapeutics, 2010; 1(1): 81–95

36. Inhibition of Snail-induced Epithelial to Mesenchymal Transition and Induction of the Tumor Metastasis Suppressor Gene, Raf-1 kinase Inhibitory Protein (RKIP) by DETANONOate

Baritaki S, Bonavida B

Forum on Immunopathological Diseases and Therapeutics, 2010; 1(3): 219–230

37. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.

Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B.

Cancer Res. 2009; 69(21):8376-85. (IF_{2017/2018}: **9.13**)

38. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.

Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B.

Oncogene. 2009; 28(40):3573-85. (IF_{2017/2018}: **6.854**)

39. Mycobacterium thermoresistibile: case report of a rarely isolated mycobacterium from Europe and review of literature.

Neonakis IK, Gitti Z, Kontos F, Baritaki S, Petinaki E, Baritaki M, Zerva L, Spandidos DA.

Indian J Med Microbiol. 2009; 27(3):264-7. (IF_{2017/2018}: **1.157**)

40. Evaluation of GenoType mycobacteria direct assay in comparison with Gen-Probe Mycobacterium tuberculosis amplified direct test and GenoType MTBDRplus for direct detection of Mycobacterium tuberculosis complex in clinical samples.

Neonakis IK, Gitti Z, Baritaki S, Petinaki E, Baritaki M, Spandidos DA.

J Clin Microbiol. 2009; 47(8):2601-3. (IF_{2017/2018}: **4.959**)

41. Report of 2 indigenous cases of leprosy from a European country: use of polymerase chain reaction-restriction fragment length polymorphism analysis of hsp65 gene for identification of Mycobacterium leprae directly from a clinical sample.

Neonakis IK, Gitti Z, Kontos F, Baritaki S, Zerva L, Krambovitis E, Spandidos DA.

Diagn Microbiol Infect Dis. 2009; 64(3):331-3. (IF_{2017/2018}: **2.314**)

- 42. BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma.**
Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA.
Cell Cycle. 2009; 8(9):1402-8. (IF_{2017/2018}: **3.304**)
- 43. YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels.**
Baritaki S, Chatzinikola AM, Vakis AF, Soultz N, Karabetsos DA, Neonakis I, Bonavida B, Spandidos DA.
Cancer Invest. 2009; 27(2):184-92. (IF_{2017/2018}: **2.053**)
- 44. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.**
Huerta-Yepe S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B.
Nitric Oxide. 2009; 20(1):39-52. (IF_{2017/2018}: **4.367**)
- 45. K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma.**
Lyronis ID, Baritaki S, Bizakis I, Krambovitis E, Spandidos DA.
Pathol Oncol Res. 2008; 14(3):267-73. (IF_{2017/2018}: **2.433**)
- 46. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases.**
Bonavida B, Baritaki S, Huerta-Yepe S, Vega MI, Chatterjee D, Yeung K.
Nitric Oxide. 2008; 19(2):152-7. (IF_{2017/2018}: **4.367**)
- 47. High prevalence of Human Herpes Virus 8 (HHV-8) in patients with Warthin's tumors of the salivary gland.**
Dalpa E, Gourvas V, **Baritaki S**, Miyakis S, Samaras V, Barbatis C, Sourvinos G, Spandidos DA.
J Clin Virol. 2008; 42(2):182-5. (IF_{2017/2018}: **3.101**)
- 48. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.**
Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, Soufla G, Zoras O, Spandidos DA.
Cancer Lett. 2008; 264(1):145-61. (IF_{2017/2018}: **6.508**)
- 49. Analysis of the beta-lactam resistance phenotypes of Escherichia coli. An 8-year survey conducted in Greece.**
Neonakis IK, Baritaki S, Georgiladakis A, Spandidos DA.
Roum Arch Microbiol Immunol. 2008; 67(1-2):10-3.
- 50. Activation-induced cell death signalling in CD4+ T cells by staphylococcal enterotoxin A.**
Porichis F, Morou A, Baritaki S, Spandidos DA, Krambovitis E.
Toxicol Lett. 2008; 176(1):77-84. (IF_{2017/2018}: **3.499**)
- 51. Mycobacterial species diversity at a general hospital on the island of Crete: first detection of Mycobacterium lentiflavum in Greece.**

- Neonakis IK, Gitti Z, Kourbeti IS, Michelaki H, Baritaki M, Alevraki G, Papadomanolaki E, Tsafaraki E, Tsouri A, Baritaki S, Krambovitis E, Spandidos DA.
Scand J Infect Dis. 2007; 39(10):875-9. (IF_{2017/2018}: **2.201**)
- 52. The NO TRAIL to YES TRAIL in cancer therapy**
Lee JY, Huerta-Yepez S, Vega M, Baritaki S, Spandidos DA, Bonavida B.
Int J Oncol. 2007; 31(4):685-91. (IF_{2017/2018}: **3.571**)
- 53. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.**
Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR.
Br J Haematol. 2007; 138(4):467-78. (IF_{2017/2018}: **5.206**)
- 54. Resistance status of Mycobacterium tuberculosis on the island of Crete, Greece.**
Neonakis IK, Gitti Z, Baritaki M, Kourbeti IS, Baritaki S, Petinaki E, Maraki S, Krambovitis E, Spandidos DA.
Eur J Clin Microbiol Infect Dis. 2007; 26(8):607-9. (IF_{2017/2018}: **2.537**)
- 55. Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection.**
Baritaki S, Sifakis S, Huerta-Yepez S, Neonakis IK, Soufla G, Bonavida B, Spandidos DA.
Int J Oncol. 2007; 31(1):69-79. (IF_{2017/2018}: **3.571**)
- 56. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators.**
Apostolakis S, Krambovitis E, Vlata Z, Kochiadakis GE, Baritaki S, Spandidos DA.
Thromb Res. 2007; 121(3):387-95. (IF_{2017/2018}: **3.266**)
- 57. Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications.**
Baritaki S, Apostolakis S, Kanellou P, Dimanche-Boitrel MT, Spandidos DA, Bonavida B.
Adv Cancer Res. 2007; 98:149-90. (IF_{2017/2018}: **6.422**)
- 58. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.**
Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B.
Mol Cancer Ther. 2007; 6(4):1387-99. (IF_{2017/2018}: **5.365**)
- 59. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth.**
Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, Berenson JR.
Blood. 2007; 110(1):287-95. (IF_{2017/2018}: **16.601**)
- 60. Biophysical characterization of V3-lipopeptide liposomes influencing HIV-1 infectivity.**
Rizos AK, Baritaki S, Tsikalas I, Doetschman DC, Spandidos DA, Krambovitis E.
Biochem Biophys Res Commun. 2007; 355(4):963-9. (IF_{2017/2018}: **2.559**)

- 61. Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients.**
Panagiotakis SH, Soufla G, Baritaki S, Sourvinos G, Passam A, Zagoreos I, Stavrianeas N, Spandidos DA.
AIDS Res Hum Retroviruses. 2007; 23(1):10-8. (IF_{2017/2018}: **1.935**)
- 62. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease.**
Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopoulos D, Spandidos DA.
Thromb Res. 2007; 119(1):63-71. (IF_{2017/2018}: **3.266**)
- 63. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population.**
Apostolakis S, Baritaki S, Krambovitis E, Spandidos DA.
J Clin Virol. 2005; 34(4):310-4. (IF_{2017/2018}: **3.101**)
- 64. In vitro inhibition of R5 HIV-1 infectivity by X4 V3-derived synthetic peptides.**
Baritaki S, Dittmar MT, Spandidos DA, Krambovitis E.
Int J Mol Med. 2005; 16(2):333-6. (IF_{2017/2018}: **2.928**)
- 65. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.**
Soufla G, Baritaki S, Sifakis S, Zafiropoulos A, Spandidos DA.
Int J Biol Markers. 2005; 20(1):18-27. (IF_{2017/2018}: **1.767**)
- 66. Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas.**
Lyronis ID, Baritaki S, Bizakis I, Tsardi M, Spandidos DA.
Int J Biol Markers. 2005; 20(1):5-10. (IF_{2017/2018}: **1.767**)
- 67. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.**
Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA.
Cancer Lett. 2005; 221(1):105-18. (IF_{2017/2018}: **6.508**)
- 68. Association between schizophrenia and DRD3 or HTR2 receptor gene variants.**
Baritaki S, Rizos E, Zafiropoulos A, Soufla G, Katsafouros K, Gourvas V, Spandidos DA.
Eur J Hum Genet. 2004; 12(7):535-41. (IF_{2017/2018}: **3.65**)
- 69. Simple electrostatic interaction mechanisms in the service of HIV-1 pathogenesis.**
Krambovitis E, Zafiropoulos A, Baritaki S, Spandidos DA.
Scand J Immunol. 2004; 59(2):231-4. (IF_{2017/2018}: **2.563**)
- 70. NOD2 insertion mutation in a Cretan Crohn's disease population.**
Roussomoustakaki M, Koutroubakis I, Vardas EM, Dimoulios P, Kouroumalis EA, Baritaki S, Koutsoudakis G, Krambovitis E.
Gastroenterology. 2003; 124(1):272-3; author reply 273-4. (IF_{2017/2018}: **20.773**)

71. Light scattering and in vitro biocompatibility studies of poly (vinyl pyrrolidone) derivatives with amino-acid-dependent groups.

Baritaki S, Tzanakakis GN, Alifragis J, Zafiropoulos A, Tashmukhamedov RI, Tsatsakis A, Shtilman MI, Rizos AK, Krambovitis E.

J Biomed Mater Res. 2002; 63(6):830-7. (IF_{2017/2018}: **3.221**)

72. Immunoreactivity and light scattering studies of polyvinyl pyrrolidone polymeric derivatives

S. Baritaki, E. Krambovitis, J. Alifragis, A.K. Rizos, M. Shtilman, A.M. Tsatsakis

Journal of Non-Crystalline Solids. 2002; 307 (310):898–904. (IF_{2017/2018}: **2.6**)

73. Ionic interaction of the HIV-1 V3 domain with CCR5 and deregulation of T lymphocyte function.

Baritaki S, Zafiropoulos A, Sioumpara M, Politis M, Spandidos DA, Krambovitis E.

Biochem Biophys Res Commun. 2002; 298(4):574-80. (IF_{2017/2018}: **2.559**)

74. Dys-regulation of effector CD4+ T cell function by the V3 domain of the HIV-1 gp120 during antigen presentation.

Zafiropoulos A, Baritaki S, Vlata Z, Spandidos DA, Krambovitis E.

Biochem Biophys Res Commun. 2001; 284(4):875-9. (IF_{2017/2018}: **2.559**)

75. Generation of human anti-MUC3 IgG antibodies after in vitro immunization of naive peripheral blood B-lymphocytes.

Baritaki S, Zafiropoulos A, Georgopoulos E, Souris S, Krambovitis E.

Cancer Immunol Immunother. 2001; 50(2):109-14. (IF_{2017/2018}: **4.9**)

76. V3 induces in human normal cell populations an accelerated macrophage-mediated proliferation-apoptosis phenomenon of effector T cells when they respond to their cognate antigen.

Zafiropoulos A, Baritaki S, Sioumpara M, Spandidos DA, Krambovitis E.

Biochem Biophys Res Commun. 2001; 281(1):63-70. (IF_{2017/2018}: **2.559**)

77. Nitric oxide production by pre-implantation embryos in response to embryotoxic factors.

Athanassakis I, Aifantis I, Baritakis S, Farmakiotis V, Koumantakis E, Vassiliadis S.

Cell Physiol Biochem. 2000; 10(3):169-76. (IF_{2017/2018}: **5.5**)

Γ. Ελληνόγλωσσες Δημοσιεύσεις

1. SARS: Η πρώτη πανδημία του 21^{ου} αιώνα

Σ. Μπαριτάκη, Σπαντίδος Δ..

Ιατρική Επικαιρότητα, Ιούλιος – Αύγουστος 2003, (2292-2293)

Δ. Βιβλία / Κεφάλαια σε Ξενόγλωσσα Βιβλία

1. Book: ‘Prognostic and Therapeutic Applications of RKIP in Cancer’, Elsevier, 1st Edition, Eds: B. Bonavida, S. Baritaki, ISBN: 978-0-12-81 9612-0, 3/2/2020.

2. B. Bonavida, S. Baritaki*, 'RKIP and YY1: The 'good' and the 'bad' shields in the protection of cancer spreading and resistance to therapies' In: *Atlas of Science*. February 19, 2018 (<https://atlasofscience.org/rkip-and-yy1-the-good-and-the-bad-shields-in-the-protection-of-cancer>)
3. S. Baritaki, B. Bonavida. 'Nitric oxide inhibits EMT via regulation of the NF-kB/Snail/RKIP loop'. In: *Nitric Oxide and Cancer: Prognosis, Prevention and Therapy*. Human Press. 2010, PartIV, pages: 209-235
4. B. Bonavida, S. Huerta-Yepez, S. Baritaki, J. Berenson. 'Nitric oxide donors are a new class of anti-cancer therapeutics for the reversal of resistance and inhibition of metastasis'. In: *Nitric Oxide and Cancer: Prognosis, Prevention and Therapy*. Human Press. 2010, PartVII, pages: 459-478
5. B. Bonavida, S. Huerta-Yepez, M. Vega, S. Baritaki*. Nitric Oxide-Induced Immunosenitization to Apoptosis by Fas-L and TRAIL. In: *Sensitization of Cancer cells for Chemo/immuno/radio-therapy*. Human Press. 2008, Edition 1, Chapter 13.

ΑΝΑΚΟΙΝΩΣΕΙΣ

- **Ανακοινώσεις καταχωρημένες σε πρακτικά Διεθνών Συνεδρίων**

1. Stress, Inflammation and colon cancer: A neuropeptide-driven crosstalk”

S. Baritaki

World Cancer Congress 2018, August 13-15, 2018, Rome, ITALY

2. ‘Nitric Oxide: A multifaceted target for reversal of cancer cell pleiotropic properties by NO-modulating therapies’

S. Baritaki

International Meeting on Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Disorders, October 4-5, 2018, Siena, ITALY

3. ‘Regulation of Drug Resistance Via the Overexpression of Phospho-RKIP (P-RKIP) in Multiple Myeloma: Dephosphorylation of P-RKIP Reverses Drug Resistance’

D. Chatterjee, **S. Baritaki**, B. Bonavida

Blood 2017 130:4971

59th ASH Annual Meeting, December 9-12 2017, Washington DC, USA

4. ‘High Expression of the Resistant Factor YY1 and Low Expression of the RKIP chemosensitizing Factor in Multiple Myeloma: Delineation of Several Crosstalk Pathways that Regulate the Expression of these Factors’

S. Wottrich, S. Kaufhold, **S. Baritaki**, B. Bonavida

Blood 2017 130:5417

59th ASH Annual Meeting, December 9-12 2017, Washington DC, USA

5. ‘Corticotropin-Releasing Hormone Receptor 2 Mediates Epithelial Cell Proliferation, Apoptosis and Mucosal Repair Following Colitis’

Jill M. Hoffman, **Stavroula Baritaki**, Jonathan J. Ruiz, Aristeia Sideri, Charalabos Pothoulakis

Gastroenterology, Vol. 148, Issue 4, S-102, April 2015

Digestive Disease Week, May 2015, Washington DC, USA

6. ‘Corticotropin-Releasing Hormone Receptor 2 (CRHR2) Inhibits Colorectal Cancer Immunoescape Through Regulation of Fas/FasL Signaling’

Jonathan Gevorkian, Hein W. Verspaget, Daniel W. Hommes, Lin Chang, Charalabos Pothoulakis, **Stavroula Baritaki**

Gastroenterology, Vol. 148, Issue 4, S-732, April 2015

Digestive Disease Week, May 2015, Washington DC, USA

7. ‘Corticotropin-releasing hormone receptor 2 signaling promotes mucosal healing during colitis

Hoffman JM, **Baritaki S**, Ruiz JJ, Sideri A, Pothoulakis C’.

Gastroenterology, Vol. 146, Issue 5, S-825, May 2014

Digestive Disease Week, May 2014, Chicago, IL, USA

8. ‘Inhibition of Corticotropin-Releasing Hormone Receptor 2 (CRHR2) Expression in Colorectal Correlates With Tumor Growth and EMT *In Vitro* and *In Vivo*, Poor Patient Survival and Increased Risk for Distant Metastases’

Rodriguez J, Iliopoulos D, Huerta Yopez S, Hoffman JM, Baay-Gusman GJ, Tirado-Rodriguez AB, Ka Man Law I, Hommes DW, Pothoulakis C, **Baritaki S**

Gastroenterology, Vol. 146, Issue 5, S-814, May 2014

Digestive Disease Week, May 2014, Chicago, IL, USA

9. 'Corticotropin releasing hormone receptor 2 signaling promotes mucosal healing following colitis'
Hoffman JM, **Baritaki S**, Ruiz JJ, Sideri A, Pothoulakis C.
Federation of Neurogastroenterology and Motility Meeting, September 2014, Guangzhou, CHINA
10. 'Altered Ucn2 and CRHR2 expression in colon cancer. Implications in tumor growth and EMT'
J Rodriguez, C Pothoulakis, **S Baritaki**
Cancer Research 73 (8 Supplement):1484-1484 · August 2013
104th AACR Annual Meeting, April 2013, Washington, DC, USA
11. 'Effects of Urocortin 2 and Corticotropin-releasing hormone receptor 2 in colorectal cancer growth and metastasis'
J Rodriguez, C Pothoulakis, and **S Baritaki**
Gastroenterology, Vol. 144, Issue 5, S-281, May 2013
DDW Annual Meeting, May 2013, Orlando, FL, USA
12. Yin Yang 1 (YY1) regulates EMT via transcriptional activation of Snail and its overexpression in cancer stem cells (CSCs) in prostate cancer. Clinical significance
Stavroula Baritaki, Valentina Rapozzi, Rosana Pelayo, Mario Vega, Sara Huerta-Yepez, Benjamin Bonavida.
Mol Cancer Ther 2013;12(11 Suppl): Abstract nr A53.
AACR-NCI-EORTC International Conference, 2013 Oct 19-23; Boston, MA.
13. 'Stable Water Clusters-Mediated Molecular Alterations in Human Melanoma Cell Lines'
B. Bonavida, **S. Baritaki**
Forum on immunopathological diseases and therapeutics 3(3-4):253-259 · January 2012
14. 'Galiximab disrupts the dysregulated NF- B/YY1/Snail/BclXL circuit that regulates the resistance of B-NHL cell lines: Sensitization to chemo-immunotherapeutic drugs'
Vega GG, Martinez-Panigua M, Yepez S, Baritaki S, Bonavida B
Cancer Research 06/2012; 72(8 Supplement): Abstract nr 766
103rd AACR Annual Meeting, March 31 - April 04, 2012; Chicago, Illinois
15. 'The overexpressed transcriptional repressor EZH2 in prostate and breast cancer regulates the underexpressed metastasis suppressor RKIP'
K. Yeung, **S. Baritaki**, G. Ren, H. Marathe, J. Feng, S. Park, S. Vinod Saladi, I. de la Serna, E. Keller, B. Bonavida
102nd AACR Annual Meeting, April 2 - 6, 2011, Orlando, FL, USA
16. 'Identification of a novel mechanism by which the BH3 mimetic obatoclax sensitizes non-Hodgkin's lymphoma tumor cells to TRAIL-mediated apoptosis'
Martinez-Paniaqua M., Yepez S, **Baritaki S**, Gonzalez Bonilla CR, Vega M
Cancer Research 07/2011; 71(8 Supplement): Abstract nr 3499
102nd AACR Annual Meeting, April 2 - 6, 2011, Orlando, FL, USA
17. Inhibition of the metastasis suppressor RKIP by EZH2 and YY1
S. Baritaki, K. Yeung, S. Huerta-Yepez, B. Bonavida
Cancer Research 04/2011; 71(8 Supplement): Abstract nr 2162
102nd AACR Annual Meeting, April 2 - 6, 2011, Orlando, FL, USA

18. 'Dual roles of Raf-1 kinase inhibitor protein (RKIP) in the regulation of both tumor cell resistance to apoptotic stimuli and epithelial to mesenchymal transition (EMT)'
S. Baritaki, KC Yeung, B Bonavida
Forum of Immunopathological Diseases and Therapeutics, Vol 2, 2011, Issue 1, pages 95-109
1st International meeting on prognostic and therapeutic applications of RKIP involvement in cancer March 19-20, 2010, Los Angeles, CA, USA
19. 'The NO donor DETANONOate inhibits the EMT phenotype in human metastatic prostate carcinoma cell lines: pivotal roles of inhibition of NF- κ B and Snail activities and induction of RKIP'
S. Baritaki, S. Huerta-Yepe, A. Sahakyan, A. R. Jazirehi, K. Yeung, B. Bonavida.
Cancer Research 01/2011; 70(8 Supplement): Abstract nr 1466
101st AACR Annual Meeting, April 17 - 21, 2010, Washington DC, MD, USA
20. 'A novel function in metastasis for YY1 overexpression in the initiation of the EMT phenotype'
S. Baritaki, S. Huerta-Yepe, K. Yeung, Neonakis I, B. Bonavida.
Cancer Research 01/2011; 70(8 Supplement): Abstract nr 2290
101st AACR Annual Meeting, April 17 - 21, 2010, Washington DC, MD, USA
21. 'Correlation between the overexpression of the metastasis-inducer transcription factors, Snail and Yin Yang 1 and BRAF mutations in a large panel of melanoma cell lines'
S. Huerta-Yepe, S. Ekmekcioglu, G. Antonio-Andres, C. M. Rivera-Pazos, G. Baay-Guzman, G. Malaponte, A. R. Jazirehi, **S. Baritaki**, E. Grimm, B. Bonavida.
Cancer Research 01/2011; 70(8 Supplement): Abstract nr 2242
101st AACR Annual Meeting, April 17 - 21, 2010, Washington DC, MD, USA
22. 'BRAF and NRAS mutations in melanoma regulate the phosphorylation and inactivation of RKIP, the metastasis suppressor and immune surveillance cancer gene product'
Huerta-Yepe S, Suhendan E, Rivera-Pazos CM, Antonio-Andres G, Vega M, Baay-Guzman G, Melaponte G, **Baritaki S**, Yeung KC, Grimm E, Bonavida B
Cancer Research 2010; 70(8 Supplement): Abstract nr 3374
101st AACR Annual Meeting, April 17 - 21, 2010, Washington DC, MD, USA
23. 'Resistance of human melanoma to MART-1/H1AA.1 specific CTL (F5 CTL)-killing: poor recognition, low MART-1 expression and reversal of resistance'
A. Jazirehi, **S. Baritaki**, Bonavida B, J. Economou
Cancer Research 2010; 70(8 Supplement): Abstract nr 1928
101st AACR Annual Meeting, April 17 - 21, 2010, Washington DC, MD, USA
24. 'Inhibition of the RKIP and PTEN-transcription repressor Snail in B-NHL by the proteasome inhibitor NPI-0052: Roles of RKIP and PTEN induction in the reversal of resistance to TRAIL apoptosis'
S. Baritaki, K. Wu, K. Yeung, H. Chen, J. Berenson, M. Palladino, B Bonavida.
BLOOD 113 (11): 942, 678 NOV 16 2009
51st ASH Annual Meeting, December 8-11, 2009, New Orleans, USA
25. 'The Anti-CD 20 Mab R603 Induces PTEN and RKIP Expression in B-NHL Cells: Role in Inhibition of Constitutively Activated Akt and NF- κ B Survival Anti-Apoptotic Pathways'
L. Militello, **S. Baritaki**, E. Suzuki, M.I. Vega, M. Salcedo, B. Bonavida
BLOOD 113 (11): 2346, 678 NOV 16 2009

51st ASH Annual Meeting, December 8-11, 2009, New Orleans, USA

26. 'Inhibition of the EMT Cascade in Metastasis by Nitric Oxide Donors: Novel Anti Metastatic Drugs'
S. Baritaki, S. Huerta-Yepe, K. Yeung, K. Wu, D. Spandidos, B. Bonavida
INT. J. MOL. MED. (2009). 24 (sup. 1), p:S72
14th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology, Oct 2009, Loutraki, GREECE
27. 'Nitric oxide-mediated inhibition of EMT in tumor metastatic prostate cells through suppression of Snail and induction of the metastasis suppressor gene product, RKIP'
S. Baritaki
1st International Workshop on Nitric Oxide in Cancer Therapy, September 11-12, 2009, Dijon, FRANCE
28. 'Yin-Yang 1 (YY1) as a tumor immune-suppressor gene product'
S. Baritaki
Forum of Immunopathological Diseases and Therapeutics, Vol 1, 2010, Issue 1-2, pages 17-30
1st International Workshop on Prognostic and Therapeutic Roles of Yin Yang 1 in Cancer, May 24-26, 2009, Catania, ITALY
29. 'Reversal of acquired resistance of CTL-resistant human melanoma cell lines to CTL-mediated killing by Bortezomib (Velcade): Pivotal role of the NF-kB anti-apoptotic survival pathway in immuno-sensitization'
A. Jazirehi, G Nang, R. Jandali, J. Quatromoni, Y. Wang, **S. Baritaki**, B. Bonavida, A. Ribas and J. Economou
Cancer Research, May 1 2009 (69) (9 Supplement) Abstract nr 2419.
100th AACR Annual Meeting, Apr 18-22, 2009; Denver, Colorado, USA
30. 'The anti-cancer NF-kB inhibitor, DHMEQ, exerts direct cytotoxicity, reverses resistance and inhibits metastasis'
S. Baritaki, A. Jazirehi, S. Huerta-Yepe, M. Vega, K. Yeung, A. Katsman, E. Suzuki, K. Umezawa, B. Bonavida.
100th AACR Annual Meeting, April 18 - 22, 2009, Denver, Colorado, USA
31. 'The proteasome inhibitor NPI-0052 inhibits metastasis via inhibition of snail-induced emt and induction of the tumor metastasis suppressor RKIP'
S. Baritaki, A. Chapman, K. Yeung, M. Palladino, B. Bonavida.
100th AACR Annual Meeting, April 18 - 22, 2009, Denver, Colorado, USA
32. 'NO donors sensitize resistant prostate cancer, *in vitro* and *in vivo*, to apoptosis by chemotherapeutic drugs'
S. Huerta-Yepe, M. Vega, G.J. Baay-Guzman, **S. Baritaki**, B. Bonavida
100th AACR Annual Meeting, April 18 - 22, 2009, Denver, Colorado, USA
33. 'The Novel Proteasome inhibitor NPI-0052 induces the expression of Raf-1 kinase inhibitor protein RKIP) in B-NHL via inhibition of the transcription repressor Snail: Roles of Snail and RKIP in sensitization to TRAIL apoptosis'
S. Baritaki, A. Chapman, K. Wu, K. Yeung, D. Spandidos, J. Berenson, M. Palladino, B Bonavida.
BLOOD 112 (11): 2611, 904 NOV 16 2008
50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA
34. 'Unique Pattern of Raf-1 kinase Inhibitory protein (RKIP) expression in multiple myeloma (MM): RKIP overexpression and RKIP phosphorylation is common in MM tumor cells'
S. Baritaki, S. Huerta-Yepe, M. cabera-Munoz, C. Rivera-Pazos, B. waterman, K. Yeung, H. Chen, J. Berenson, B. Bonavida.

BLOOD 112 (11): 2729, 943 NOV 16 2008

50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA

35. 'Identification of Differentially expressed genes in the rituximab-resistant clone (Ramos RR1) compared to wildtype sensitive Ramos: Therapeutic Implications in Rituximab-resistance'

S. Baritaki, J.A. Rodriguez, G. Helguera, M. Martinez-Paniagua, M. Vega, S. Huerta-Yepez, A. Jazirehi, D.A. Spandidos, M.L. Penichet, B. Bonavida.

BLOOD 112 (11): 3770, 1291 NOV 16 2008

50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA

36. 'Prognostic significance of both the cytoplasmic and nuclear overexpression of Yin-Yang 1 (YY1) among patients with multiple myeloma (MM)'

S. Huerta-Yepez, C. Rivera-Pazos, M. Libra, **S. Baritaki**, H. Chen, JR. Berenson, B. Bonavida.

BLOOD 112 (11): 2730, 943 NOV 16 2008

50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA

37. 'Galiximab (anti-CD80 mAb)-induced cell triggering results in the inhibition of the constitutive NF- κ B activity in Raji: Contrasting roles of Snail and RKIP in the regulation of drug/immuno resistance.

M. Martinez-Paniagua, M. Vega, S., Huerta-Yepez, **S. Baritaki**, JR. Berenson, H. Hariharan, B. Bonavida.

BLOOD 112 (11): 3623, 1239, NOV 16 2008

50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA

38. 'Molecular Mechanism by which Rituximab sensitizes B-NHL cells to TRAIL mediated apoptosis: Induction of RKIP and DR5 expression via inhibition of NF- κ B, Snail and YY1'

M. Vega, S. M. Martinez-Paniagua, Huerta-Yepez, K. Yeung, **S. Baritaki**, B. Bonavida.

BLOOD 112 (11): 1596, 566, NOV 16 2008

50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA

39. 'Expression, Role in Transformation and Prognostic Significance of the Transcription Factor YY1 in Non-Hodgkin's Lymphoma: Analyses in NHL Tissues by Experimental and Bioinformatic Approaches'

M. Libra, G Castellano, S. Baritaki, S. Huerta-Yepez, G. Ligresti, L. Militello, G. Malaponte, F. Stivala, S. Canevari, B. Bonavida.

BLOOD 112 (11): 1900, p976-977, NOV 16 2008

50th ASH Annual Meeting, December 6-9, 2008, San Francisco, California, USA

40. 'Regulation of multiple myeloma cell survival and resistance by overexpression of the phosphorylated form of RAF-1 kinase inhibitor protein (RKIP)'

S. Baritaki, S. Huerta-Yepez, B. Waterman, K. Wu, A. Jazirehi, K. Yeung, M. Libra, H. Chen, D. Spandidos, J. Berenson, B. Bonavida.

INT. J. MOL. MED. (2008). 18 (sup. 1), p:S78:

10th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology. Oct 2008, Xersonisos, Crete, GREECE

41. 'Inhibition of Snail-induced EMT and induction of the tumor metastasis suppressor/immune cancer gene RKIP by the proteasome inhibitor NPI-0052'

S. Baritaki, A. Chapman, K. Yeung, D. Chatterjee, H. Cheng, J. Berenson, K. Umezawa, M. Palladino, D. Spandidos, B. Bonavida.

INT. J. MOL. MED. (2008). 19 (sup. 1), p:S97

10th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology. Oct 2008, Xersonisos, Crete, GREECE

42. 'The Snail attack by the turtle: A tale of metastasis and its inhibitors'
B. Bonavida, **S. Baritaki**, G. Malaponte, M. Libra, J. Berenson, D. Spandidos, K. Yeung
INT. J. MOL. MED. (2008). 19 (sup. 1), p:S86
10th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology. Oct 2008, Xersonisos, Crete, GREECE
43. 'Novel mechanisms underlying the BH3 mimetic obatoclax (GX015-070) induced tumor cell sensitization to TRAIL apoptosis: Inhibition of NF- κ B and downstream Bcl-xL, Mcl-1 and YY1 and upregulation of DR5'
M. Martinez, **S. Baritaki**, M.I. Vega, C.R.G. Bonilla, D.A. Spandidos, B. Bonavida
INT. J. MOL. MED. (2008). 19 (sup. 1), p:S84
10th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology. Oct 2008, Xersonisos, Crete, GREECE
44. 'Inhibition of Snail-induced EMT and induction of the tumor metastasis suppressor/immune cancer gene RKIP by the proteasome inhibitor NPI-0052: Role in chemo/immunosensitization and metastasis'
S. Baritaki, K. Yeung, D. Chatterjee, H. Cheng, J. Berenson, M. Palladino, B. Bonavida
99th AACR Annual Meeting, April 12-15, 2008, San Diego, California, USA
45. 'Induction of Raf-1 kinase inhibitory protein (RKIP) by the proteasome inhibitor NPI-0052 and reversal of B-NHL resistance to apoptosis'
S. Baritaki, K. Yeung, D. Chatterjee, M. Palladino, B. Bonavida.
BLOOD 110 (11): 809, 248a Part 1 NOV 16 2007
49th ASH Annual Meeting, December 8-11, 2007, Atlanta, Georgia, USA
46. 'Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP is Common in MM Tumor cells'
S. Baritaki, S. Huerta-Yepez, K.C. Yeung, M. Penichet, H. Chen, D. Shalitin, J. Berenson, B. Bonavida.
BLOOD 110 (11): 4852, 1301a Part 2 NOV 16 2007
49th ASH Annual Meeting, December 8-11, 2007, Atlanta, Georgia, USA
47. 'Galiximab sensitizes malignant human B cell lines to apoptosis by chemotherapeutic drugs'
S. Baritaki, E. Suzuki, M. Vega, S.N. Ho, K. Hariharan, B. Bonavida.
BLOOD 110 (11): 3591, 1050a Part 1 NOV 16 2007
49th ASH Annual Meeting, December 8-11, 2007, Atlanta, Georgia, USA
48. 'Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab)'
M.I. Vega, S. Huerta-Yepez, **S. Baritaki**, M.A. Martinez-Paniagua, C.R. Gonzalez-Bonilla, B. Bonavida.
BLOOD 110 (11): 2350, 695a Part 1 NOV 16 2007
49th ASH Annual Meeting, December 8-11, 2007, Atlanta, Georgia, USA
49. Therapeutic preclinical application of NO donor (e.g. DETANONOate) and CDDP in prostate tumor xenograft regression: molecular mechanism of synergy achieved in apoptosis
S. Huerta-Yepez, V. Balis, A. Hernandez-Cueto, S. Huerta, O. Muñoz-Hernandez, M.I. Vega, K. Yeung, B. Waterman, **S. Baritaki**, D. Spandidos, B. Bonavida

NITRIC OXIDE-BIOLOGY AND CHEMISTRY 17 (2007) S20–S29

1st International Conference on Nitric Oxide and Cancer, November 26-28 2007 Paris, FRANCE

50. 'Pivotal role of RKIP induction in Nitric Oxide (NO) – induced tumor cell sensitization to TRAIL-mediated apoptosis via YY1 inhibition and DR5 over-expression'

S. Baritaki, S. Huerta-Yepez, K.C. Yeung, B. Bonavida.

NITRIC OXIDE-BIOLOGY AND CHEMISTRY 17;S16-S16:2007

1st International Conference on Nitric Oxide and Cancer, November 26-28 2007 Paris, FRANCE

51. 'Chemo and immuno-sensitizing activities of nitric oxide (NO) and reversal of tumor resistance to apoptotic stimuli: Therapeutic implications'

Bonavida, B; Garban, H; Huerta-Yepez, S, Baritaki S

NITRIC OXIDE-BIOLOGY AND CHEMISTRY 17;S13-S13:2007

1st International Conference on Nitric Oxide and Cancer. November 26-28 2007 Paris, FRANCE

52. Nitric oxide mimics rituximab (chimeric anti-CD20 mAb)-induced chemo/immuno-sensitization of resistant B-non Hodgkin's lymphoma

Vega, MI; Huerta-Yepez, S; Balis, V; S. Baritaki

NITRIC OXIDE-BIOLOGY AND CHEMISTRY; (17) S28-S28 2007

1st International Conference on Nitric Oxide and Cancer. November 26-28 2007 Paris, FRANCE

53. 'RKIP as a New Immunosurveillance Gene: Pivotal Role in the Regulation of Tumor Cell Response to Cytotoxic Immunotherapy'

S.Baritaki, K.C. Yeung, D. Chatterjee, A. Katsman, D.A. Spandidos, B. Bonavida.

10th International Symposium on Molecular Medicine and 12th World Congress on Advances in Oncology, October 11-13, 2007, Xersonisos, Crete, GREECE

54. 'Nitric Oxide (NO) induced sensitization of tumor cells to TRAIL-mediated apoptosis via induction of RKIP, DR5 overexpression and inhibition of YY1'

S. Baritaki, A. Katsman, A. Wu, S. Huerta-Yepez, K.C. Yeung, D.A. Spandidos, and B. Bonavida.

98th AACR Annual meeting, 14-18, April, 2007, Los Angeles, USA

55. 'Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor RKIP via YY1 inhibition and DR5 upregulation'

S. Baritaki, A. Katsman, D. Chatterjee, K.C. Yeung, D.A. Spandidos and B. Bonavida.

CANCER RESEARCH, Volume 67, Issue 9 Supplement, pp. 2401

98th AACR Annual meeting, 14-18, April, 2007, Los Angeles, USA

56. 'Correlation between overexpression of YY1 and downregulation of DR5 in prostate tumor arrays: novel mechanism of escape from immune surveillance'

S. Huerta-Yepez, A. Hernandez-Cueto, M. Vega, B. Sanchez-Arallano, D. Garcia-Herrera, D. Hernandez-Cueto, C.R. Gonzalez-Bonilla, S. Baritaki, M. Libra, B. Bonavida.

98th AACR Annual meeting, 14-18, April, 2007, Los Angeles, USA

57. 'Nitric oxide sensitizes B-NHL cells to TRAIL-mediated apoptosis through induction of RKIP, inhibition of YY1 and upregulation of DR5'

S. Baritaki, A. Katsman, S. Huerta-Yepez, K.C. Yeung, J. Berenson, B. Bonavida.

BLOOD 108 (11): 231B-231B 4604 Part 2 NOV 16 2006

48th ASH Annual Meeting, 9-12 December 2006, Orlando, Florida, USA

58. 'Induction of RKIP and inhibition of the transcription repressor YY1 in B-NHL by the novel proteasome inhibitor NPI-0052 and sensitization to TRAIL-induced apoptosis'

E. Suzuki, S. Huerta-Yepez, **S. Baritaki**, M. Palladino, B. Bonavida.

BLOOD 108 (11): 677B-677B 2391 Part 2 NOV 16 2006.

48th ASH Annual Meeting, 9-12 December 2006, Orlando, Florida, USA

59. 'Rituximab-mediated upregulation of PTEN expression and inhibition of both the P13K/AKT pathway and pleiotrophin (PTN) expression in B-NHL: Roles in cell growth inhibition and chemosensitization'

Suzuki E, Chem HM, **Baritaki S**, Berenson J, Bonavida B..

BLOOD 108 (11): 673A-673A 2374 Part 1 NOV 16 2006.

48th ASH Annual Meeting, 9-12 December 2006, Orlando, Florida, USA

60. 'Rituximab-mediated sensitization of B-NHL cells lines to TRAIL-induced apoptosis: involvement of YY1 suppression and DR5 upregulation'

M.I. Vega, S. Huerta-Yepez, **S. Baritaki**, C. Bonilla-Gonzalez, B. Bonavida

BLOOD 108 (11): 676B-676B 2387 Part 2 NOV 16 2006.

48th ASH Annual Meeting, 9-12 December 2006, Orlando, Florida, USA

61. '2-methoxyestradiol sensitizes B-NHL cells to TRAIL-mediated apoptosis via inhibition of HIF-1 alpha, NF-κB, YY1 and induction of DR5 expression'

Huerta-Yepez S, Vega MI, **Baritaki S**, Bonavida B.

BLOOD 108 (11): 241B-241B 4642 Part 2 NOV 16 2006.

48th ASH Annual Meeting, 9-12 December 2006, Orlando, Florida, USA

62. 'Over Expression of YY1 and RKIP in Multiple Myeloma (cell lines and MM tissues)'

S. Baritaki, S. Huerta-Yepez, A. Katsman, K.C. Yeung, D. Chatterjee, H. Chen, J. Berenson, B. Bonavida

BLOOD 108 (11): 347B-348B 5035 Part 2 NOV 16 2006.

48th ASH Annual Meeting, 9-12 December 2006, Orlando, Florida, USA

63. 'Evaluation of VEGF and TGFB1 mRNA expression profiles as markers of malignant transformation in cytological cervical specimens'

Baritaki S, Sifakis S, Soufla G, Spandidos DA.

EUROPEAN JOURNAL OF CANCER (2006). 4 (sup. 1), p: 47.

4th International conference in cancer prevention, 16 - 18 February 2006, St. Gallen, SWITZERLAND

64. 'TGF-β1 and VEGF expression is regulated at the protein level in endometrial cancer'

Soufla G., Porichis F., Sifakis S., **Baritaki S.**, Spandidos DA.

EUROPEAN JOURNAL OF CANCER (2006). 4 (sup. 1), p:47.

4th International conference in cancer prevention, 16 - 18 February 2006, St. Gallen, SWITZERLAND

65. 'Reversal of resistance to apoptotic stimuli by alteration of membrane fluidity; therapeutic implications'

Baritaki S., Kanellou P., Apostolakis S., Spandidos D.A., Bonavida B.

97th Annual AACR meeting, 2006, Washington DC, USA

66. 'Identification of novel therapeutic targets in the reversal of Rituximab and drug resistant non Hodgkins lymphoma: chemosensitization by specific pharmacological inhibitors'

- B. Bonavida, A. Jazirechi, **S. Baritaki**, E. Suzuki.
INT. J. MOL. MED. (2006). 18 (sup. 1), p: S7
9th International Symposium on Molecular Medicine and 11th World Congress on Advances in Oncology. Oct 2006, Xersonissos, Crete, GREECE
67. Human herpes virus 8 infection is implicated in salivary gland carcinoma.
V. Gourvas, E. Dalpa. G. Sourvinos, **S. Baritaki**, S. Miyakis, V. Samaras, C. Barbatis, D. Spandidos.
INT. J. MOL. MED. (2006). 18 (sup. 1), p:S74
9th International Symposium on Molecular Medicine and 11th World Congress on Advances in Oncology. Oct 2006, Xersonissos, Crete, GREECE
68. 'Effects of angiotensin converting enzyme inhibitors on the chemokine receptors of the THP-1 cells'
S. Apostolakis, Z. Vlata, G. Kochiadakis, **S. Baritaki**, E. krambovitis, D.A. Spandidos
INT. J. MOL. MED. (2006). 18 (sup. 1), p:S78
9th International Symposium on Molecular Medicine and 11th World Congress on Advances in Oncology. Oct 2006, Xersonissos, Crete, GREECE
69. 'HIV-1 gp120/V3 promotes activation induced cells death to CD4 T lymphocytes during antigen presentation'
F. Porichis, Z. Vlata, **S. Baritaki**, D.A. Spandidos, E. Krambovitis.
INT. J. MOL. MED. (2006). 18 (sup. 1), p:S79
9th International Symposium on Molecular Medicine and 11th World Congress on Advances in Oncology. Oct 2006, Xersonissos, Crete, GREECE
70. 'CDDP sensitizes prostate cancer cells to TRAIL-mediated apoptosis via inhibition of NF-κB/YY1 pathway'
Baritaki S, Neshat M, Huerta-Yeppez S, Sakai T, Spandidos DA, Bonavida B.
ECCO 13 – the European Cancer Conference, 2005, Paris, FRANCE
71. 'Mechanisms of transcriptional upregulation of DR5 by chemotherapeutic drugs and sensitization to TRAIL-induced apoptosis'
Baritaki S, Neshat M, Huerta-Yeppez S, Murdock B, Sakai T, Spandidos DA, Bonavida B.
96th Annual AACR Meeting), April, 2005, Anaheim, California, USA
72. 'Sensitization of prostate cancer cells to TRAIL-induced apoptosis by CDDP: Involvement of NF-κB, YY1 and RKIP in upregulation of DR5 expression'
M. Neshat, **S. Baritaki**, S. Huerta-Yeppez, A. Katsman, T. Delgado, K. Umezawa, T. Sakai, K. C. Yeung, D. Chatterjee, B. Bonavida.
JOURNAL OF CLINICAL ONCOLOGY 23 (16): 238S-238S Part 1 Suppl. S Jun 1 2005
41st ASCO Annual Meeting May 2005, Orlando, FL, USA
73. 'Inhibition of constitutive NF-κB or YY1 activity sensitizes prostate cancer cells to TRAIL-induced apoptosis via upregulation of DR5 expression'
M. S. Neshat, S. Huerta-Yeppez, **S. Baritaki**, S. E. Escoto-Chavez, B. Murdock, K. Umezawa, T. Sakai, K. C. Yeung, D. Chatterjee, B. Bonavida.
41st ASCO Annual Meeting May 2005, Orlando, FL, USA
74. 'Overexpression and preferential nuclear translocation of the transcription factor Yin Yang 1 (YY1) in human bone marrow-derived multiple myeloma'
Huerta-Yeppez S, **Baritaki S**, Hernandez-Cuesto A.

BLOOD 106 (11): 948A-948A 3394 Part 1 NOV 16 2005

47th ASH Annual Meeting, Atlanta, Georgia, USA

75. 'The Yin-Yang 1 (YY1) transcription repressor regulates tumor cell resistance to apoptotic stimuli: New target for prognosis and therapeutic intervention'
Bonavida B., Garban H., Huerta-Yepez S., Vega M., Gordon S., Neshat M., **Baritaki S.**, Spandidos D.A.
INT. J. MOL. MED. (2005). 16 (sup. 1), p: S53.
8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology, Oct 2005, Xersonissos, Crete, GREECE
76. 'Evaluation of BRAF gene mutation in esophageal squamous cell carcinomas'
Lyronis I, **Baritaki S.**, Bizakis I, Tsardi M, Spandidos DA.
INT. J. MOL. MED. (2005). 16 (sup. 1), p: S55.
8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology, Oct 2005, Xersonissos, Crete, GREECE
77. 'Mutational analysis of p16^{INK4a}, p14^{ARF} and p15^{INK4b} genes in actinic keratosis'
Kanellou P., **Baritaki S.**, Sourvinos G., Soufla G., Stratigos A., Zoras O., Spandidos D.A.
INT. J. MOL. MED. (2005). 16 (sup. 1), p: S55.
8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology, Oct 2005, Xersonissos, Crete, GREECE
78. 'Reversal of resistance to apoptotic stimuli by alteration of membrane fluidity; therapeutic implications'
Baritaki S., Soufla G., Spandidos D.A., Bonavida B.
INT. J. MOL. MED. (2005). 16 (sup. 1), p: S58
8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology, Oct 2005, Xersonissos, Crete, GREECE
79. '280M variant of CXC3 receptor 1 gene is associated with lower prevalence and decreased angiographic severity of coronary artery disease'
Apostolakis S., **Baritaki S.**, Kochiadakis G., Igoumenidis N.E., Panutsopoulos D., Spandidos D.A.
INT. J. MOL. MED. (2005). 16 (sup. 1), p: S59
8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology, Oct 2005, Xersonissos, Crete, GREECE
80. '280M variant of CX3C receptor 1 gene is associated with reduced risk for coronary artery disease'
Apostolakis S, Kochiadakis GE, **Baritaki S.**
EUROPEAN HEART JOURNAL 26: 138-138 P1033 Suppl. 1 Sep 2005
ESC Congress, Sept 2005, Stockholm, SWEDEN
81. 'A evidence for the ionic nature of the HIV-1 gp120/V3 interaction with CCR5 that affects biological events in lymphocytes'
Krambovitis E., Porichis F., Vlata Z., **Baritaki S.**, Spandidos D.
INT. J. MOL. MED. (2005). 16 (sup. 1), p: S62.
8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology Oct 2005, Xersonissos, Crete, GREECE
82. 'The use of superantigens for the study of HIV gp120/V3 mediated biological events in CD4+ T lymphocytes'

Porichis F., Vlata Z., **Baritaki S.**, Spandidos D.A., Krambovitis E.

INT. J. MOL. MED. (2005). 16 (sup. 1), p: S63.

8th International Symposium on Molecular Medicine and 10th World Congress on Advances in Oncology, Oct 2005, Xersonissos, Crete, GREECE

83. 'Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with the malignant transformation of the uterine cervix'

Soufla G, **Baritaki S**, Sifakis S, Zafiropoulos A, Koumantakis E, and Spandidos DA

18th EACR Meeting, July, 2004, Innsbruck, AUSTRIA

84. 'Disruption of mRNA co-expression patterns of growth factors implicated in angiogenesis and malignant transformation of the uterine cervix'

Soufla G, Sifakis S, **Baritaki S**, Zafiropoulos A, Koumantakis E, and Spandidos DA.

The XVIIIth European Congress of Obstetrics and Gynaecology", May 2004, Athens, GREECE

85. 'Transcriptional upregulation of DR5 by chemotherapeutic drugs (CDDP, ADR) and sensitization to TRAIL-mediated apoptosis: Inhibition of the transcriptional repressor Yin Yang 1 (YY1)'

Baritaki S, Huerta-Yepez S, Murdock B, Sakai T, Spandidos DA, Bonavida B.

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S54.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

86. 'Chemo and Immuno-sensitization of prostate cancer cell lines by the NF-κB inhibitor, DHMEQ.

Huerta-Yepez S., Vega M., Umezawa K., **Baritaki S**, Spandidos DA., Bonavida B'

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S54.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

87. 'Molecular ionic interactions as a mechanism of extracellular signal regulation: The gp120/V3-CCR5 paradigm'

Krambovitis E, **Baritaki S**, Zafiropoulos A, Spandidos DA..

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S50.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

88. 'Evaluation of human papilloma and Epstein-Barr viruses' incidence in esophageal squamous cell carcinomas'

Lyronis I, **Baritaki S**, Bizakis I, Tsardi M, Spandidos DA.

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S49.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

89. 'Frequencies of HIV/AIDS protective mutations in SDF-1 chemokine and CC chemokine receptors genes within the Cretan population'

Apostolakis S, **Baritaki S**, Krambovitis E, Spandidos DA.

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S50.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

90. 'Deregulation of p53, Bax, Bcl-2 and Mdm2 transcription in cervical carcinogenesis'

Soufla G, **Baritaki S**, Sifakis S, Zafiropoulos A, Spandidos DA.

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S53.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

91. 'Herpesvirus detection in HIV positive patients: Correlation with clinical data'

Panagiotakis S, Soufla G, **Baritaki S**, Zafiropoulos A, Passam A, Sourvinos G, Zagoreos I, Stavrianeas N.G, Spandidos DA.

INT. J. MOL. MED. (2004). 14 (sup. 1), p: S67.

7th International Symposium on Molecular Medicine and 9th World Congress on Advances in Oncology Oct 2004, Xersonissos, Crete, GREECE

92. 'Association study between Schizophrenia and DRD3 or HTR2 receptor gene variants.

Baritaki S, Risos E, Zafiropoulos A, Soufla G, Gourvas V, Spandidos DA.

INT. J. MOL. MED. (2003). 12 (sup. 1), p: S60.

6th International Symposium on Molecular Medicine and 8th World Congress on Advances in Oncology, Oct 2003, Xersonissos, Crete, GREECE

93. 'The role of V3 in the HIV-1 induced pathogenesis'

Krambovitis E, **Baritaki S**, Zafiropoulos A, Spandidos DA.

INT. J. MOL. MED (2003). 12 (sup. 1), p:S56.

6th International Symposium on Molecular Medicine and 8th World Congress on Advances in Oncology, Oct 2003, Xersonissos, Crete, GREECE

94. 'The importance of ionic charges in the interaction of the HIV-1 V3 principal neutralizing **domain** with the amino-terminal of CCR5: Implications on T cell function'

S. Baritaki, A. Zafiropoulos, M. Sioumpara, M. Politis, D.A. Spandidos, E. Krambovitis.

INT. J. MOL. MED (2002). 10 (sup. 1), p: S36.

5th International Symposium on Molecular Medicine and 7th World Congress on Advances in Oncology Oct 2002, Xersonissos, Crete, GREECE

95. 'The V3_induced phenomenon of activation-apoptosis in normal effector CD4+ T cells, is inhibited by the CCR5 agonist, RANTES'

S. Baritaki, A. Zafiropoulos, Z. Vlata, D.A. Spandidos, E. Krambovitis.

INT. J. MOL. MED. (2001). 8 (sup. 1), p: S52.

4th International Symposium on Molecular Medicine and 6th World Congress on Advances in Oncology, Oct. 2001, Xersonissos, Crete, GREECE

96. 'The V3 region of HIV-1 gp120 signalling pathway promotes activation induced cell death'

A. Zafiropoulos, **S. Baritaki**, D.A. Spandidos, E. Krambovitis.

INT. J. MOL. MED (2001). 8 (sup. 1), p: S63.

4th International Symposium on Molecular Medicine and 6th World Congress on Advances in Oncology, Oct. 2001, Xersonissos, Crete, GREECE

97. 'A potential mechanism for CD4+ T cell depletion in HIV-1 infection: Antigen activation-induced cell death of physiological effector CD4+ T cells by the V3 domain of HIV-1 gp120'

E. Krambovitis, **S. Baritaki**, A. Zafiropoulos, D.A. Spandidos.

INT. J. MOL. MED. (2001). 8 (sup. 1), p: S65.

4th International Symposium on Molecular Medicine and 6th World Congress on Advances in Oncology, Oct. 2001, Xersonissos, Crete, GREECE

98. 'The semi-conserved domain of the HIV-1 gp120 V3 region dysregulates the physiological function of effector CD4+ T cells'

A. Zafiropoulos, **S. Baritaki**, M. Sioumpara, D.A. Spandidos, E. Krambovitis

INT. J. MOL. MED. (2001). 8 (sup. 1), p: S75.

4th International Symposium on Molecular Medicine and 6th World Congress on Advances in Oncology, Oct. 2001, Xersonissos, Crete, GREECE

99. 'Light scattering and immunoreactivity studies of PVP derivatives with amino acid-dependent groups'

S. Baritaki, J. Alifragis, E. Krambovitis, M. Shtilman, M. Tsatsakis, A. K. Rizos.

4th International Discussion Meeting on Relaxations in Complex Systems. June 2001, Xersonissos, GREECE

• Ανακοινώσεις σε Ελληνικά Επιστημονικά Συνέδρια

1. 'Διερεύνηση του ρόλου ρυθμιστών του stress στον καρκίνο του παχέως εντέρου'

A. Κυριαζή, **Σ. Μπαριτάκη**

Συνέδριο Κλινικής και Μεταφραστικής Ογκολογίας, Ηράκλειο 11-13 Νοεμβρίου 2020

2. 'LncRNAs: Novel Biomarkers for Cancer Stem Cells (CSCs)'

Σ. Μπαριτάκη

Συνέδριο Κλινικής και Μεταφραστικής Ογκολογίας, Ηράκλειο 7-9 Νοεμβρίου 2019

3. 'Light scattering and In Vitro Biocompatibility studies of poly (vinyl pyrrolidone) derivatives with amino-acid-dependent groups'

S. Baritaki, J. Alifragis, E. Krambovitis, M. Shtilman, M. Tsatsakis, A. K. Rizos

3rd Annual Hellenic Symposium on Toxicology. Heraklion, Greece, 6-10 November 2002.

4. 'Η περιοχή V3 του ιού HIV-1 προκαλεί ένα ειδικό φαινόμενο ενεργοποίησης απόπτωσης σε φυσιολογικά αναμνηστικά T λεμφοκύτταρα'

Σ. Μπαριτάκη, A. Ζαφειρόπουλος, H. Κραμποβίτης

26^ο Ετήσιο Πανελλήνιο Ιατρικό Συνέδριο 15-20, Μαΐου 2000, Αθήνα

(2^ο Πανελλήνιο Βραβείο Βασικής Έρευνας)

5. 'In vitro παραγωγή ανθρώπινων αντισωμάτων εναντίον του πρωτεϊνικού σκελετού βλεννινών (mucins) που υπερ-εκφράζονται στον καρκίνο του παχέως εντέρου'

Σ. Μπαριτάκη, H. Κραμποβίτης

4^ο Πανελλήνιο Συνέδριο Ανοσολογίας, 9-12 Δεκεμβρίου 1998, Θεσσαλονίκη ...